38th week of 2015 patent applcation highlights part 9 |
Patent application number | Title | Published |
20150258136 | Therapeutic use of hydrogen molecules - The invention concerns a kit for preventing or treating oxidative stress in humans or animals by means of therapeutically active hydrogen molecules. The hydrogen molecules are formed by reacting a base metal with aqueous acids or bases and by reacting a saline hydride with water or aqueous acids. | 2015-09-17 |
20150258137 | PLASMA AND BRAIN PHARMACOKINETICS OF PREVIOUSLY UNEXPLORED LITHIUM SALTS - Despite its narrow therapeutic window, lithium is regarded as the gold standard comparator and benchmark treatment for mania. Attempts to find new drugs with similar therapeutic activities have yielded new chemical entities. However, these new drugs have yet to match the many bioactivities attributable to lithium's efficacy for the treatment of neuropsychiatric diseases. Consequently, an intense effort for re-engineering lithium therapeutics using crystal engineering is underway. The evaluation of pharmacokinetics of previously unexplored lithium salts with organic anions (i.e. lithium salicylate) has found that these lithium salts exhibit profoundly different pharmacokinetics compared to the more common FDA approved salt, lithium carbonate, in rats. Remarkably, lithium salicylate produced elevated blood and brain levels of lithium beyond 48 hours post-dose without the sharp peak that contributes to the toxicity problems of current lithium therapeutics. | 2015-09-17 |
20150258138 | Clay Mineral for Reducing Inorganic Phosphates, In Particular In Renal Replacement Therapy - The invention relates to a clay mineral for use as an agent for reducing the concentration of inorganic phosphate in liquids, in particular in bodily fluids or dialysis liquids, in order to treat hyperphosphatemia, in particular in a renal replacement therapy, wherein before use, the clay mineral is thermally treated at a temperature between 400° C. and 800° C., preferably between 500° C. and 700° C., in particular preferably at 550° C., over a time period of 60 min to 240 min, preferably 90 min to 180 min, in particular preferably 120 min. | 2015-09-17 |
20150258139 | METHODS FOR TREATMENT OF CANCER USING LIPOPLATIN - Applicant provides herein a method for inhibiting the growth of a solid tumor or treating cancer in a patient comprising, or alternatively consisting essentially of, or yet further consisting of administering to the patient an effective amount of Lipoplatin monotherapy in a first dose and a second dose, thereby inhibiting the growth of the solid tumor or treating cancer in the patient. | 2015-09-17 |
20150258140 | METHODS FOR TREATING CANCER WITH REDUCED RENAL TOXICITY - A method is provided for inhibiting the growth of a tumor in a cancer patient or treating a cancer patient, wherein the cancer patient has renal insufficiency. The method requires the administration of an effective amount of Lipoplatin. A second chemotherapeutic drug can also be administered to the patient. The second chemotherapy can be administered prior to or after the Lipoplatin therapy or simultaneously. | 2015-09-17 |
20150258141 | ELECTROLYTIC SPORTS DRINK COMPOSITION - A composition taken before, during, or after exercise; comprising: potassium; sodium; magnesium; chromium; vitamin B12; vitamin C; vitamin E; and sucrose. A method of formulating a composition including potassium; sodium; magnesium; chromium; vitamin B12; vitamin C; vitamin E; and sucrose. The composition is believed to be significant to athletes with sickle cell disease (SCD) and/or sickle cell trait to avoid dehydration and aid in muscle recovery. | 2015-09-17 |
20150258142 | DECELLULARIZED PLEURAL MATRIX - The present invention pertains to the development of biologically derived extracellular matrices (ECM) derived from decellularized pleura tissue. Such matrices are useful in many clinical and therapeutic applications, including the repair, reconstruction, sealing, or joining of tissue, tendons, bones, and/or ligaments. In addition, the present invention features methods of making a biologically derived ECM derived from decellularized pleura tissue. The invention further features laminated ECM matrices. | 2015-09-17 |
20150258143 | METHOD OF PROVIDING CELLULAR THERAPY USING MODIFIED NATURAL KILLER CELLS OR T LYMPHOCYTES - A method of decreasing cytokine production and release is disclosed. In one embodiment, the method comprises the step of providing cytotoxic cells to a subject wherein the cells are preferably natural killer cells or T lymphocytes and are genetically modified to express a chimeric antigen receptor comprising a first element that is an extracellular antigen receptor and a second intracellular element that is a signaling moiety comprising altered ADAP-dependent or Fyn-dependent signaling such that downstream signaling causing cytokine release is decreased. Specific modifications of CD137 and NKG2D cytoplasmic tails are described. Additionally, methods to develop and screen drug compounds capable of compromising the binding between ADAP and Fyn and disrupting the downstream release of cytokines are described. | 2015-09-17 |
20150258144 | Allograft tolerance induction - A method inducing chimerism and allograft tolerance by co-infusion of stein/progenitor-like cells and donor cells, wherein the donor cells can be bone marrow cells. The method also comprises the conditioning comprising depletion of CD4+ and CD8+ T-cells and administration of low doses of anti-neoplastic drugs. The inventive method comprises an aspect wherein allograft tolerance is induced without systemically suppressing the immune system. | 2015-09-17 |
20150258145 | TISSUE TRANSPLANT COMPOSITIONS AND METHODS FOR USE - Provided are transplants and methods for augmenting formation and restoration of organ and tissue, for example, bone formation, by administering autologous or allogeneic human embryonic-like adult stem cells (ELA cells). Also provided is a method for augmenting formation of tissues and organs by administering a transplant having ELA stem cells or combination of ELA stem cells. | 2015-09-17 |
20150258146 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ORTHOPEDIC PATHOLOGIES - The present invention relates to a gingival fibroblast-derived product for use in the prevention or treatment of orthopedic pathologies in an individual. | 2015-09-17 |
20150258147 | ISOLATED CARDIAC STEM CELLS AND METHODS OF THEIR USE - The present invention relates to isolated populations of cardiac stem cells. The invention provides methods for characterizing, isolating, and culturing cardiac stem cells from human tissue samples. The invention also provides compositions and methods useful for treating cardiac disease. | 2015-09-17 |
20150258148 | Compositions, Methods and Systems for Cellular Differentiation from Stem Cells - The present invention is directed to methods and systems directed to altering the differentiation of a cell, more particularly to biasing a potent cell, such as a mesenchymal stem cell, by contacting such cell with a protein having properties of bone morphogenic protein-4. The contacting may be achieved via genetic modification, and the resulting cell may be or have characteristics of a pre-adipocyte. Pre-adipocyte cells so-obtained, and their progeny, may be used for various purposes, including in cosmetic and other surgical therapies and treatments. | 2015-09-17 |
20150258149 | ADULT BONE MARROW CELL TRANSPLANTATION TO TESTES CREATION OF TRANSDIFFERENTIATED TESTES GERM CELLS, LEYDIG CELLS AND SERTOLI CELLS - This invention pertains to the discovery that stem cells (e.g., bone marrow stem cells) transplanted directly into a testicular environment are transdifferentiated into bona fide Sertoli cells, and/or Leydig cells, and/or and germ cells. This provides a mechanism for the treatment of male infertility and/or testosterone deficiency. Thus, in one embodiment, this invention provides a method of treating infertility or testosterone deficiency in a male mammal. The method typically involves implanting stem cells into the testes of the mammal whereby the stem cells differentiate into germ cells and/or Sertoli cells and/or Leydig cells thereby reducing infertility and/or testosterone deficiency. | 2015-09-17 |
20150258150 | BACILLUS AMYLOLIQUEFACIENS STRAIN - A novel strain of | 2015-09-17 |
20150258151 | GUT BARRIER DYSFUNCTION TREATMENT AND PREVENTION - Methods are disclosed for treating and preventing gut barrier dysfunction or an illness associated with gut barrier dysfunction in a subject comprising administering to the subject bacterium that produce an indole or an indole metabolite and for identifying compounds and bacteria for use in treatment and prevention of gut barrier dysfunction or an illness associated with gut barrier dysfunction. | 2015-09-17 |
20150258152 | PLANT SPECIES THAT ARE AN EFFECTIVE TREATMENT FOR VIRAL INFECTIONS IN ANIMALS AND PLANTS - Methods of making compositions by extracting a plant of the genus | 2015-09-17 |
20150258153 | METHODS AND COMPOSITIONS OF CANNABIS EXTRACTS - In one embodiment, a method is provided for obtaining an extract from a | 2015-09-17 |
20150258154 | BETALAIN COMPOSITIONS AND METHODS THEREFOR - Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood. | 2015-09-17 |
20150258155 | PROCESS FOR OBTAINING CAFFEOYLQUINIC ACIDS-RICH EXTRACTS FROM HELIANTHUS ANNUUS - The present invention relates to extracts of deoiled | 2015-09-17 |
20150258156 | Sustainable and Improved Delivery Vehicle for Imparting Therapeutic and Nutritive Levels of Flaxseed to Mammals - A means for imparting healthful dosages of flaxseed to mammals and a muffin-based regimen for providing a healthful and therapeutic dosage of Alpha-Linolenic Acid (ALA), an essential omega-3 fatty acid, in combination with organic and/or all-natural sub-elements selected from the group consisting of cinnamon, fiber, bananas, walnuts, carrots—optionally, without any negative impact upon the subject articles' ability to maintain their palatable and gustatorily attractive character. Sustainable mixtures enable healthy living without sacrificing taste. | 2015-09-17 |
20150258157 | FORMULATIONS FOR THE TREATMENT AND PREVENTION OF OBESITY - Disclosed are compositions containing: a) | 2015-09-17 |
20150258158 | COMPOSITIONS AND METHODS FOR INHIBITION OF TRIGLYCERIDE SYNTHESIS VIA SYNERGISTIC COMBINATION OF BOTANICAL FORMULATIONS - Compositions and methods for inhibition of triglyceride synthesis via synergistic combination of botanical extracts are described. Specifically, the present invention relates to treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, or the like, as well as managing skin oil production through a synergistic inhibition of diacylglycerol acyltransferase-I (DGAT-I) enzyme involved in the triglyceride synthesis and modulation of sterol regulatory element binding protein Ic (SREBP-Ic) and/or peroxisome proliferator activated receptor gamma coactivator I-alpha (PGCIα). | 2015-09-17 |
20150258159 | Method of Modulating Oxidative Stress, Inflammation, or Impaired Insulin Sensitivity with Grape Seed Extract - Method for modulating oxidative stress, inflammation, and impaired insulin sensitivity in a subject by using a grape seed extract, the method being useful in modulating post-prandial oxidative stress, inflammation, and impaired insulin sensitivity in patients suffering from Metabolic Syndrome (MetS). | 2015-09-17 |
20150258160 | Method of Treating Metabolic Syndrome with Grape Seed Extract - Method for modulating oxidative stress, inflammation, and impaired insulin sensitivity in a subject by using a grape seed extract, the method being useful in modulating post-prandial oxidative stress, inflammation, and impaired insulin sensitivity in patients suffering from Metabolic Syndrome (MetS). | 2015-09-17 |
20150258161 | PLANT EXTRACT HYDROLYSATES AND ANTIBACTERIAL PRODUCT CONTAINING THE SAME - The invention relates to a hydrolyzate from at least one extract of at least one plant material selected from the group consisting of at least one genus: | 2015-09-17 |
20150258162 | COMPOSITION FOR COSMETIC, PHARMACEUTICAL AND DIETARY APPLICATIONS - A composition including 0.5-40 weight % vegetable extract, 30-90 weight % sugar and 0.5-30 weight % phospholipid for cosmetic, pharmaceutical or dietary uses. | 2015-09-17 |
20150258163 | Jucara and Acai Fruit-Based Compositions - The present invention relates to stable, palatable, freeze-dried, fruit-based compositions. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based compositions from Açai fruit and Jucara fruit. | 2015-09-17 |
20150258164 | Jucara and Acai Fruit-Based Compositions - The present invention relates to stable, palatable, freeze-dried, fruit-based compositions. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based compositions from Açai fruit and Jucara fruit. | 2015-09-17 |
20150258165 | METHODS FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA AND RELATED DISORDERS - The disclosure provides methods of treating X-linked hypophosphatemia, related bone demineralization and renal phosphate wasting disorders in a mammalian subject. The methods comprise administering to the subject an effective amount of a polyarginine peptide | 2015-09-17 |
20150258166 | COMPOSITIONS AND METHODS FOR CARDIAC TISSUE PROTECTION AND REGENERATION - In various aspects the present inventions provide compositions and methods for treatment of cardiac conditions. In various embodiments, the present inventions provide methods for treating a cardiac condition comprising the step of administering in a therapeutically effective amount the substantially cell free solution of an amphiphilic self-assembling peptide to a site of cardiac tissue that has been injured due to one or more of atrial fibrillation, acute myocardial infarction; valve disease, pericardial disease, congenital heart disease, congestive heart failure, and embolism. | 2015-09-17 |
20150258167 | New Treatments of Hepatitis C Virus Infection - The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus genotype 2 or 3 infection. | 2015-09-17 |
20150258168 | MODULATION OF PODOPLANIN MEDIATED PLATELET ACTIVATION - The present invention relates generally to the use of modulators of podoplanin (PDPN) mediated platelet activation. For example, an agonist or mimic of podoplanin (PDPN)/C-type lectin-like receptor 2 (CLEC-2) signaling may be used to inhibit vascular leakage or promote vascular integrity. Alternatively, an antagonist of podoplanin (PDPN)/C-type lectin-like receptor 2 (CLEC-2) signaling may be used to inhibit platelet activation. | 2015-09-17 |
20150258169 | TOPICAL PREVENTATIVE MEDICAMENT AGAINST BURNS-RELATED SYSTEMIC INFLAMMATORY RESPONSE SYNDROME - A topical preventative medicament against burns-related systemic inflammatory response syndrome containing a low-molecular-weight chaperone as the main active ingredient. | 2015-09-17 |
20150258170 | Diagnosis and Treatment of SMA and SMN Deficiency - The present invention provides for methods for diagnosing and treating a motor neuron disease. More specifically, the present invention offers new methods for diagnosing and treating SMA or SMN deficiencies and monitoring treatment. It is possible to identify a subject having a symptom of the disease, and then administer to the subject a therapeutically effective amount of one or more proteins or a gene delivery vehicle or pharmaceutical composition comprising one or more genes selected from the group consisting of Transmembrane protein 41B (Stasimon), Chromosome 19 open reading frame 54 (Rashomon), Tetraspanin 31, Poly (ADP-ribose) polymerase family member 1, Histidyl-tRNA synthetase-like, Chloride channel 7, and Nucleolar protein 1. | 2015-09-17 |
20150258171 | ALPHA-1-MICROGLOBULIN FOR USE IN THE TREATMENT OF MITOCHONDRIA-RELATED DISEASES - The present invention relates to alpha-1-microglobulin for use in the treatment of a mitochondria-related disease. | 2015-09-17 |
20150258172 | DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDES OR THEIR INHIBITORS - The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease. | 2015-09-17 |
20150258173 | COMPOSITIONS FOR MODULATING INVASION ABILITY OF A TUMOR AND METHODS THEREOF - The present invention provides a composition for modulating invasion ability of a tumor, comprising: an effective amount of an activator for a miRNA-mediated pathway or an effective amount of a modulating member in the miRNA-mediated pathway being a modulating member, and wherein the miRNA-mediated pathway is regulated by at least one miRNA selected from the group consisting of miR-346, miR-504 and miR-1179. The composition functions according to a novel model that an activator or a modulating member can regulate cellular invasion/migration of tumor via a miRNA-mediated pathway, and thereby can be a potential candidate of molecular drug to treat the tumor by modulating its invasion ability. A method for treating or preventing tumor invasion method is provided as well. Meanwhile, a method for detecting the invasive ability of a tumor in a subject and the kit thereof are also provided. | 2015-09-17 |
20150258174 | RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION - The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified uridine nucleotides or modified cytidin nucleotides. | 2015-09-17 |
20150258175 | METHOD OF TREATING CANCER - The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition. | 2015-09-17 |
20150258176 | MEDICINAL AGENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS - A medicinal composition for suppressing or preventing the metastasis of a malignant tumor, the composition comprising, as an active ingredient, at least one kind of vasoprotective agent selected from the following (i) to (iv): (i) angiotensin II receptor antagonist, (ii) HMG-CoA reductase inhibitor, (iii) ghrelin or its derivative, and (iv) adrenomedullin or its derivative; or a pharmacologically acceptable salt thereof. | 2015-09-17 |
20150258177 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH | 2015-09-17 |
20150258178 | INTRANASAL INSULIN ADMINISTRATION FOR THE PREVENTION OF ANESTHESIA-INDUCED TAU PATHOLOGY/TAUOPATHIES - Intranasal administration of insulin for a predetermined period prior to anesthesia significantly prevented anesthesia-induced tau hyperphosphorylation and cognitive impairment and enhanced brain insulin signaling in mice. Intranasal insulin thus provides a treatment for prevention of anesthesia-induced tau pathology and increased risk for tauopathies in surgical patients and may be administered to a subject prior to anesthesia, such as by administering several doses of intranasal insulin for several consecutive days prior to any anesthesia. | 2015-09-17 |
20150258179 | TREATING LIVER DISEASES - This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided. | 2015-09-17 |
20150258180 | -HEXOSAMINIDASE PROTEIN VARIANTS AND ASSOCIATED METHODS FOR TREATING GM2 GANGLIOSIDOSES - Embodiments herein include variants of β-hexosaminidase that are useful for hydrolyzing GM2 ganglioside, polynucleotides encoding the same, and related methods. In various embodiments, a variant β-hexosaminidase subunit is included wherein the variant β-hexosaminidase subunit forms a homodimer under physiological conditions and wherein the variant β-hexosaminidase subunit associates with G | 2015-09-17 |
20150258181 | CELLULAR ENHANCEMENTS IN BIOLOGICAL SYSTEMS THROUGH THE USE OF LI-POFULLERENE AND PEPTIDE GROUP COMBINATIONS - In some embodiments, a chemical composition may include C60, serrapeptase, or a tetrapeptide. The tetrapeptide may include ALA,GLU,ASP,GLY. In some embodiments, the chemical composition may include a dipeptide. The dipeptide may include carnosine or camatine. In some embodiments, the chemical composition may include at least one lipid. One or more components of the chemical composition may be suspended in and/or dissolved in the at least one lipid. At least one lipid may include olive oil or mussel oil. In some embodiments, a method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation comprising the chemical composition. The method may include inhibiting and/or ameliorating inflammation and/or a malady associated with inflammation. In some embodiments, the subject may include a human or a nonhuman mammal. Nonhuman mammals may include equines, canines, or felines. | 2015-09-17 |
20150258182 | COMPOSITIONS OF HUMAN PROTHROMBIN AND ACTIVATED FACTOR X FOR IMPROVING HEMOSTASIS IN THE TREATMENT OF BLEEDING DISORDERS - Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein. | 2015-09-17 |
20150258183 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - A method of treating depression includes locally administering a botulinum toxin subcutaneously to a face of a subject with depression, thereby treating the depression by reducing the occurrence of at least one symptom of depression. The botulinum toxin may be immunotype A or B. The toxin may be administered by injection to the forehead, scalp, face, and/or neck. | 2015-09-17 |
20150258184 | NOVEL PROTEIN MATERIAL - The invention relates to a protein material includes angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg, and cystatin and/or cystatin hydrolysate in the mass ratio to angiogenin and/or angiogenin hydrolysate of 0.003 to 0.6. | 2015-09-17 |
20150258185 | INTERLEUKIN-13 RECEPTOR ALPHA 2 PEPTIDE-BASED BRAIN CANCER VACCINES - Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant. | 2015-09-17 |
20150258186 | NUCLEIC ACID MOLECULE VACCINE COMPOSITIONS AND USES THEREOF - The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mRNA containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells. | 2015-09-17 |
20150258187 | Tuberculosis Vaccine And Method Of Using Same - Provided is a pharmaceutical composition that includes one or more inactivated | 2015-09-17 |
20150258188 | BACTERIAL OUTER MEMBRANE VESICLES - Existing methods of meningococcal OMV preparation involve the use of detergent during disruption of the bacterial membrane. According to the invention, membrane disruption is performed substantially in the absence of detergent. The resulting OMVs which retain important bacterial immunogenic components, particularly (i) the protective NspA surface protein, (ü) protein NMB2132 and (iii) protein NMB 1870. A Typical process involves the following steps: (a) treating bacterial cells in the substantial absence of detergent; (b) centrifuging the composition from step (a) to separate the outer membrane vesicles from treated cells and cell debris, and collecting the supernatant; (c) performing a high speed centrifugation of the supernatant from step (b) and collecting the outer membrane vesicles in a pellet; (d) re-dispersing the pellet from step (c) in a buffer; (e) performing a second high speed centrifugation in accordance with step (c), collecting the outer membrane vesicles in a pellet; (f) re-dispersing the pellet from step (e) in an aqueous medium. | 2015-09-17 |
20150258189 | HEPATITIS C VIRUS PARTICLES FORMATION PROMOTER, AND METHOD OF PRODUCING HEPATITIS C VIRUS PARTICLES - A HCV particle formation promoter is capable of promoting formation of HCV particles in culture cells, and a method enhances production of HCV particles. A method evaluates an anti-HCV agent candidate substance, and a method produces a HCV vaccine. The HCV particle formation promoter includes as an active ingredient a statin or a pharmaceutically acceptable salt thereof. Addition of the statin or pharmaceutically acceptable salt thereof to HCV-infected culture cells can promote formation of infectious HCV particles and enhance production of the particles. In addition, an anti-HCV agent candidate substance is evaluated by culturing HCV-infected cells in the presence of the HCV particle formation promoter and the anti-HCV agent candidate substance. Further, a HCV vaccine is produced by using HCV particles produced by the method of enhancing production of HCV particles. | 2015-09-17 |
20150258190 | NICOTINAMIDE AS ADJUVANT - The invention relates to methods for enhancing the protective immunity elicited by an immunogen that comprise administering an immunomnodulatory compound to a patient separately but simultaneously with, or prior or subsequent to, the administration of a vaccine. In particular, the present invention relates to the use of nicotinamide and derivatives thereof and benzamide and derivatives thereof in enhancing the protective immunity elicited by an immunogen. | 2015-09-17 |
20150258191 | ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION - An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidisation device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber. | 2015-09-17 |
20150258192 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) AND IDIOPATHIC PULMONARY FIBROSIS (IPF) - The described invention provides compositions and methods for reducing lung allograft dysfunction after lung transplant and for treating a severe pulmonary fibrosis characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject. The methods comprise administering to a subject in need thereof a composition comprising an antibody component comprising a therapeutic amount of an anti-CD44 antibody; and an MK2 inhibitor component comprising a therapeutic amount of an MK2 inhibitor (MK2i) polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or at least one peptide functionally equivalent to the therapeutic domain thereof selected from a polypeptide of amino acid sequence KALARQLAVA (SEQ ID NO: 8), a polypeptide of amino acid sequence KALARQLGVA (SEQ ID NO: 9) and a polypeptide of aminoacid sequence KALARQLGVAA (SEQ ID NO: 2), or a functional equivalent thereof, and a pharmaceutically acceptable carrier. | 2015-09-17 |
20150258193 | DIAGNOSTIC MARKER FOR TREATMENT OF CEREBRAL ISCHEMIA - Identification of candidates for treatment and treatment of subjects experiencing cerebral ischemia wherein the treatment employs a thrombolytic or thrombectomy agent and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are determined by testing the blood of a patient for total S-100B or for S-100BB as a marker of blood brain barrier integrity. | 2015-09-17 |
20150258194 | MODULATING TRANSENDOTHELIAL MIGRATION AND RECRUITMENT OF GRANULOCYTES BY MODULATING C-MET PATHWAY - Disclosed are granulocytes and their role in both cancer and inflammation. More particularly, it was found that c-Met expressed by granulocytes is important in transmigration and recruitment of the granulocytes. It is shown that reducing c-Met-mediated transmigration of granulocytes sustains tumor progression, indicating that c-Met-mediated granulocyte transmigration should actually be maintained because it is beneficial in treatment of cancers, particularly cancers that otherwise show resistance to c-Met inhibition. Reducing c-Met-mediated transmigration on the other hand is particularly useful in conditions characterized by an excessive immune response, such as asthma. | 2015-09-17 |
20150258195 | POLYMERIC NANOCARRIERS WITH LIGHT-TRIGGERED RELEASE MECHANISM - Near infrared radiation at a wavelength that induces resonance in water is used to remotely activate thermal plasticization of polymeric particles to trigger the release of encapsulated molecules from the particles. Nanocarriers formed from biocompatible hydrophilic polymers may be used to deliver encapsulated molecules to tissue with a reversible transition that allows repeated activations for extended release of the payload. | 2015-09-17 |
20150258196 | DELIVERY OF NAPROXEN AND OTHER COMPOUNDS - The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these. | 2015-09-17 |
20150258197 | EUTECTIC ISOMETHEPTENE MUCATE - The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of racemic isometheptene mucate and mannitol or (R)-isometheptene mucate and mannitol. | 2015-09-17 |
20150258198 | Pharmaceutical microparticulate compositions of polypeptides - The present invention refers to pharmaceutical microparticulate compositions of biologically active polypeptides and methods of forming and using such compositions. More particularly, microparticle compositions for sustained release of biologically active polypeptides are provided. By using particular pharmaceutical excipients or their specific quantity, compositions of biologically active polypeptides with desired release profile can be prepared. The microparticle compositions of this invention comprise a biocompatible polymer, a biologically active polypeptide, and pharmaceutical excipients. | 2015-09-17 |
20150258199 | METHOD FOR SILK FIBROIN GELATION USING SONICATION - This invention provides for a process of rapidly forming silk fibroin gelation through ultrasonication. Under the appropriate conditions, gelation can be controlled to occur within two hours after the ultrasonication treatment. Biological materials, including viable cells, or therapeutic agents can be encapsulated in the hydrogels formed from the process and be used as delivery vehicles. | 2015-09-17 |
20150258200 | PRESSURE-SENSITIVE HYDROGEL AND METHOD OF USE - Embodiments of the disclosure may include a pressure sensitive hydrogel composition. The composition may include a liquid solvent, a polymer, and an acid gas. The composition may be capable of having a fluid phase in which the acid gas is dissolved in the solvent and the polymer is dissolved in the solvent, and the composition may be capable of having a gel phase in which the acid gas is not dissolved in the liquid solvent and the polymer is precipitated out of the solvent. The composition may also include a chemical compound or a pharmaceutical agent that can be released after the composition is delivered to a target tissue region. | 2015-09-17 |
20150258201 | Combined enteropathogen recombinant construct - The inventive subject matter relates to a construct comprising antigens derived from multiple enterobacteria including | 2015-09-17 |
20150258202 | ANTHOCYANIDIN COMPLEX FOR THE TREATMENT OF MULTIPLE MYELOMA - The subject matter of the invention is a complex of delphinidin and a sulfoalkyl ether β-cyclodextrin for use as a medicinal drug, in particular in the treatment of multiple myeloma. | 2015-09-17 |
20150258203 | DRUG DELIVERY CONJUGATES CONTAINING UNNATURAL AMINO ACIDS AND METHODS FOR USING - Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases. The invention described herein pertains to drug delivery conjugates for targeted therapy. In particular, the invention described herein pertains to drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids. | 2015-09-17 |
20150258204 | CLICKABLE POLYOXETANE CARRIER FOR DRUG DELIVERY - A polymer is provided, comprising a subunit having the formula: (I), wherein A, B, C, D, a, b, c, d, and p are defined herein. Compositions, methods of making, and methods of use are provided. | 2015-09-17 |
20150258205 | Hydrogel Prodrugs - The present invention relates to a process for the preparation of a hydrogel and to a hydrogel obtainable by said process. The present invention further relates to a process for the preparation of a hydrogel-spacer conjugate, to a hydrogel-spacer conjugate obtainable by said process, to a process for the preparation of a carrier-linked prodrug and to carrier-linked prodrugs obtainable by said process, in particular to carrier-linked prodrugs that provide for a controlled or sustained release of a drug from a carrier. In addition, the invention relates to the use of the hydrogel for the preparation of a carrier-linked prodrug. | 2015-09-17 |
20150258206 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES - The present invention provides conjugates between peptides and PEG moieties through glycerol linkers. | 2015-09-17 |
20150258207 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L | 2015-09-17 |
20150258208 | PEGYLATED OXM VARIANTS - A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or sulfo-9-fluorenylmethoxycarbonyl (FMS) is disclosed. Pharmaceutical compositions comprising the reverse pegylated oxyntomodulin and methods of using same are also disclosed. | 2015-09-17 |
20150258209 | COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES - Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof. | 2015-09-17 |
20150258210 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to an antibody comprising a GlcNAc-S(A) | 2015-09-17 |
20150258211 | HYDROGELS FOR DELIVERY OF THERAPEUTIC POLYPEPTIDES - Disclosed herein is a hydrogel composition comprising a polymer covalently linked to glutathione (GSH). Also disclosed herein is a method for providing localized delivery of one or more agents in a subject suffering from a disease. The method comprises administering to the subject a GST/GSH affinity hydrogel comprising a therapeutically effective amount of the one or more agents. | 2015-09-17 |
20150258212 | LAYERED DOUBLE HYDROXIDES - The invention relates to layered double hydroxide (LDH) materials and in particular to new methods of preparing improved LDH materials which have intercalated active anionic compounds (improved LDH-active anion materials). The improved LDH-active anion materials are characterised by their high degree of robustness, demonstrated by their high Particle Robustness Factor values, and by their ability to retain substantially all of the intercalated active anionic compound, in the absence of ion exchange conditions and/or at pH>4. | 2015-09-17 |
20150258213 | Nanotubes as Carriers of Nucleic Acids into Cells - The present invention is directed to transfection complexes of rosette nanotubes and one or more nucleic acids. | 2015-09-17 |
20150258214 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION - The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid (molecule) and disulfide-crosslinked cationic components as a (preferably non-toxic and non-immunogenic) polymeric carrier. The inventive polymeric carrier cargo complex allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an (innate and/or adaptive) immune response, preferably dependent on the nucleic acid to be transported as a cargo. The present invention also provides, pharmaceutical compositions, particularly vaccines and adjuvants, comprising the inventive polymeric carrier cargo complex and optionally an antigen, as well as the use of such the inventive polymeric carrier cargo complex and optionally an antigen for transfecting a cell, a tissue or an organism, for (gene-)therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned above. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and/or the inventive pharmaceutical composition, adjuvant or vaccine in one or more parts of the kit. | 2015-09-17 |
20150258215 | Systemic Gene Replacement Therapy for Treatment of X-Linked MyoTubular Myopathy (XLMTM) - The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLM™). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function. | 2015-09-17 |
20150258216 | MIR-21 PROMOTER DRIVEN TARGETED CANCER THERAPY - The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21. | 2015-09-17 |
20150258217 | Methods of Synthesizing and Using Peg-Like Fluorochromes - Fluorescent compounds include near infrared fluorochromes that are covalently linked to polyethylene glycol (PEG). The compounds behave like PEG in biological systems. One fluorescent compound has the formula (I): wherein R | 2015-09-17 |
20150258218 | PARTICLES, METHODS AND USES THEREOF - The present disclosure, among other things, provides a composition including a nanoscale core; a plurality of capping agent entities associated on the core; an outer encapsulant layer; and a plurality of dopant entities distributed at locations selected from the group consisting of: on or within the nanoscale core, on or between capping agent entities, on or within the encapsulating layer, and combinations thereof. Provided technologies can achieve unprecedented levels of dopant entity density and/or surface localization, which, for a SE(R)RS-active agent dopant, results in dramatically improved signal intensity and/or imaging sensitivity. | 2015-09-17 |
20150258219 | ELECTROSTATIC-BONDING-TYPE VESICLE INCLUDING METAL MICROPARTICLES - A vesicle comprising fine metal particles, which has a membrane formed from both a first polymer of (a) or (b) shown below and a second polymer of (c) or (d) shown below (with the proviso that a combination of (b) and (d) is excepted), wherein partial crosslinking occurs between a cationic segment and an anionic segment in the above polymers: | 2015-09-17 |
20150258220 | MAGNETIC RESONANCE IMAGING AND/OR SPECTROSCOPY CONTRAST AGENTS AND METHODS OF USE THEREOF - The presently disclosed subject matter demonstrates that a spin state which has zero magnetic resonance signal, but an extremely long lifetime, can be used to store magnetization, which can then be recovered into an observable transition. Coupled with hyperpolarization techniques, this permits the preparation of a wide range of contrast agent molecules for use in magnetic resonance imaging (MRI) techniques that have long effective relaxation time. | 2015-09-17 |
20150258221 | Paramagnetic Solid Lipid Nanoparticles (pSLNs) Containing Metal Amphiphilic Complexes For MRI - The present invention relates to paramagnetic solid lipid nanoparticles (pSLNs) comprising an amphiphilic paramagnetic metal chelating moiety selected from: a diazepine derivative of Formula I and a tetraazocyclododecane derivative of Formula (II): being said chelating moiety complexed to a paramagnetic metal ion selected from the group consisting of: Gd(III), Mn(II), Cr(III), Cu(II), Fe(III), Pr(III), Nd(III), Sm(III), Tb(III), Yb(III), Dy(III), Ho(III) and Er(III), or salts thereof. The invention further relates to the process for preparation of said solid lipid nanoparticles comprising amphiphilic complexes of paramagnetic metals (pSLNs) and to the use of pSLNs as MRI contrast agents in the diagnostic field. | 2015-09-17 |
20150258222 | Magnetic Nanoparticles - A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles. | 2015-09-17 |
20150258223 | RECEPTOR BINDING CONJUGATES - The present invention relates to a receptor binding conjugate which consists of an antibody, a radionuclide and folate or a folate derivative, wherein or not the conjugate possesses dual binding ability. The present invention also relates to a method and a kit to prepare, as well as a method to use, such conjugates. Furthermore, the use of a conjugate according to the present invention to prepare a pharmaceutical solution is disclosed. | 2015-09-17 |
20150258224 | LOADABLE POLYMERIC PARTICLES FOR ENHANCED IMAGING IN CLINICAL APPLICATIONS AND METHODS OF PREPARING AND USING THE SAME - Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Microspheres of the present invention may further be provided with physical and/or chemical enhancements within the particles' cores to enhance visualization of the embolized tissue using a variety of medical imaging modalities, including conventional radiography, fluoroscopy, tomography, computerized tomography, ultrasound, scintillation, magnetic resonance, or other imaging technologies. | 2015-09-17 |
20150258225 | Apparatus For Instantaneous Expansion With Vacuum And Ultrasound Waves - This invention is based on forming an apparatus in which the technologies of flash vacuum expansion and simultaneous treatment with ultrasounds are combined for various applications in the food, pharmaceutical and cosmetics industries | 2015-09-17 |
20150258226 | SUBSTRATE STORING CASE, SUBSTRATE CLEANING APPARATUS AND SUBSTRATE STORING CASE CLEANING APPARATUS - The substrate storing case includes a base being made of quartz glass, and having a supporting part that is formed on an upper surface thereof and supports a substrate. The substrate storing case includes a top cover being made of quartz glass, and being in contact with the base to cover the substrate on the upper surface of the base. The substrate includes a first absorptive member that absorbs infrared rays and generates heat. The base or the top cover has an intake port that is in communication with a space enclosed by the upper surface of the base and the top cover and is capable of being opened and closed, and an outlet port that is in communication with the space and is capable of being opened and closed. | 2015-09-17 |
20150258227 | DISPOSABLE MEMBRANE - The invention relates mainly to an apparatus comprising a chamber for physically and/or chemically treating one or more samples or products, said apparatus comprising a door for introducing samples inside the apparatus chamber or bringing samples outside the apparatus, said apparatus comprising a membrane or film defining a chamber wall inside said apparatus when the door is closed. | 2015-09-17 |
20150258228 | TOUCH INPUT DEVICE WITH PATHOGEN TRANSMISSION MITIGATION - This disclosure provides methods and systems for mitigating pathogen transmission via a touch surface of a touch input device. Mitigation is accomplished through selective touch surface sterilization and through touchscreen user interface reorganization. The touch surface includes a pixel array for illuminating selected portions of the touch surface with ultraviolet light of a sterilization wavelength based upon the received touch inputs. The selective illumination may occur while receiving a touch input or after an accumulation of touch inputs have been received. The user interface may also be reorganized based on received touch inputs in order to locate user interface icons to lesser touched locations of the touch surface. | 2015-09-17 |
20150258229 | DISPLAY APPARATUS - A display apparatus may include a display wound around a central axis in one direction and configured to be released in another direction opposite to the one direction. The display apparatus may further include a sterilization unit disposed adjacently to the display and configured to sterilize at least one wound surface of the display. | 2015-09-17 |
20150258230 | UV-C CATHETER HUB STERILIZATION AND DATA ACQUISITION SYSTEM - A hand held hub sterilization and data acquisition device includes a housing having an opening for receiving a medical device, a sterilization chamber formed in the housing, a source of UV radiation disposed within the sterilization chamber for uniform emission of UV-C radiation into the sterilization chamber, and a safety interlock mechanism. The safety interlock mechanism comprises a Hall sensor and a rare earth magnet, and wherein the Hall sensor senses the magnetic field of the magnet when the access door is closed and sends a signal to the user interface indicating a ready state for excitation of the radiation source. | 2015-09-17 |
20150258231 | DISINFECTING COMPOSITION FOR REMOVABLE DENTAL APPLIANCES - A composition for disinfecting removable dental appliances, which includes a chloramine bleaching agent, and an amino-substituted alkylsulfonic acid. | 2015-09-17 |
20150258232 | BACTERICIDAL AGENT COMPOSITION - [Problem] To provide: a bactericidal agent composition which can exhibit an excellent bactericidal effect in the presence of an organic substance and against biofilms; a method for producing the bactericidal agent composition; and a sterilization method using the bactericidal agent composition. [Solution] A bactericidal agent composition which comprises water containing ultrafine bubbles having a most frequent particle diameter of 500 nm or less and a bactericidal component. Preferably, the density of most frequent particles of the ultrafine bubbles are 10,000 particles or more and the density of ultrafine bubbles each having a particle diameter of 1000 nm or less is 1,000,000 particles or more. | 2015-09-17 |
20150258233 | DECONTAMINATION SYSTEM FOR A BUILDING OR ENCLOSURE - A decontamination system for a building comprises a disinfectant solution source with a disinfectant solution stored in a first room of the building. At least one nozzle is positioned in a second room of the building and the at least one nozzle is in fluid communication with the disinfectant source. One or more pumps are provided in fluid communication with each nozzle and the disinfectant solution source. In addition, a pressurized air supply is provided in fluid communication with each nozzle. One or more controllers is provided in signal communication with the one or more pumps and the pressurized air supply to activate the pump(s) and pressurized air supply to simultaneously deliver the disinfectant solution and pressurized air to one or more of the nozzles in a respective room. The system may also include a hub assembly with a nozzle and pump at the hub assembly to deliver disinfectant solution to the nozzle. | 2015-09-17 |
20150258234 | METHOD OF DISINFECTING ONE OR MORE SURFACES AND/OR STERILIZING AIR, AND AN APPARATUS FOR USE IN THE METHOD - A method of disinfecting one or more surfaces and an apparatus for use in the method. The method includes a securing step arranged for creating an isolation of the surfaces to be disinfected, a disinfection step for emitting UV radiation for the generation of ozone and/or for the sterilization of air from one or more ultra violet (UV) light sources, and adding the generated ozone to the isolation, and a termination step arranged for terminating the generation of ozone and terminating the securing step. | 2015-09-17 |
20150258235 | AIR SCENT DEVICE - The present invention provides methods and systems for an air scent device that includes a base that extends to an outer edge, an outer ring that extends substantially upward from the outer edge, and an outer lip that extends substantially outwardly from the outer ring. A plurality of protruding structures extend substantially upward from the base, and a scented substance disposed within the cavity. | 2015-09-17 |